Streetbeat News

TVGN

Tevogen Bio Holdings Inc.

Industry

Biotechnology

Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.

Open

1.29

Mkt cap

229M

Volume

564K

High

1.33

P/E Ratio

3.74

52-wk high

21.09

Low

1.25

Div yield

N/A

52-wk low

0.26

Tevogen Bio has filed a new patent for a predictive AI system aimed at enhancing T cell therapies, marking a significant step in its growth strategy.

Portfolio Pulse from

December 19, 2024 | 1:45 pm

Tevogen Bio Holdings Inc. is experiencing significant insider ownership and is poised for a seasonal rebound. The company develops T-cell therapies and has a promising pipeline, with TVGN 489 completing Phase 1 trials for Long COVID and COVID-19. The stock has seen price fluctuations, with potential upside from seasonal market effects.

Portfolio Pulse from

December 18, 2024 | 7:45 am

Tevogen Bio, a clinical-stage biotech company, is enhancing its organizational structure to support its growth strategy. The company is focusing on expanding its capabilities in developing T cell therapeutics for infectious diseases and cancers.

Portfolio Pulse from

November 26, 2024 | 1:15 pm

Tevogen Bio's CEO emphasizes the importance of shareholder value and considers a potential share buyback to support the company's value. The company is focused on developing T cell therapeutics for infectious diseases and cancers.

Portfolio Pulse from

November 21, 2024 | 9:15 pm

Tevogen Bio (Nasdaq: TVGN) reported its Q3 2024 financial results, highlighting a significantly improved financial position, unreported asset value on balance sheets, and an efficient business model.

Portfolio Pulse from

November 19, 2024 | 10:00 pm

Tevogen Bio, founded in 2020, has developed a significant asset portfolio while maintaining expenditures under $40 million, preparing to file its quarterly financials. The company's success is attributed to its dedicated team.

Portfolio Pulse from

November 14, 2024 | 10:15 pm

Portfolio Pulse from

November 14, 2024 | 9:00 pm

Tevogen Bio is finalizing an agreement with CD8 Technology to enhance its R&D and manufacturing capabilities. The company has secured a $36 million line of credit to support its operations.

Portfolio Pulse from

November 08, 2024 | 9:00 pm

Tevogen Bio has expanded its partnership with Microsoft to integrate AI and machine learning into its preclinical drug development processes. This collaboration aims to shorten drug development timelines and reduce costs significantly.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 2:56 pm

Tevogen Bio has regained compliance with Nasdaq's minimum bid price requirement without a reverse stock split, maintaining a closing price of $3.05.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 7:37 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.